CIML

What CIML does

CIML (Centre d'Immunologie de Marseille-Luminy) is a French public research institute founded in 1976 and based in Marseille, operating under the joint supervision (tutelle conjointe) of Aix-Marseille Université, CNRS, and Inserm. The institute is dedicated to fundamental research on the immune system across innate and adaptive immunity, with active teams in NK cell biology, innate lymphoid cells, mucosal immunity, dendritic cells, B cell immunity, and membrane dynamics and lymphocyte signaling. CIML organizes its work through 27 research teams and technology platforms and publishes findings in top-tier journals including Cell, Nature Immunology, Science Immunology, and Cancer Research. Notable contributions include the co-discovery of the Vanin enzyme family (1996) and foundational work on NK cell biology that underpinned the 1999 spin-off of Innate Pharma.

The institute's core technology portfolio combines biological research capabilities with proprietary biophotonic and computational methods. Single-molecule localization microscopy (SMLM) is used to reconstruct informative images beyond the optical diffraction limit, and the Quality Control Maps (QCM) framework, published in Biophysical Journal in April 2025, provides real-time quantitative quality control for SMLM data through analytical rather than iterative computation. CIML also runs a labeled Master of Immunology program (amideX PLUS under TIGER–France 2030 since 2024) that trains the next generation of immunologists.

CIML does not operate a commercial revenue model. Research activities are funded through public research grants and institutional support from its three supervisory bodies. Its reach is effectively through scientific publications, conference participation, doctoral and postdoctoral training, and translational collaborations with academic and pharmaceutical partners, rather than commercial product distribution. The institute celebrated its 50th anniversary in June 2025 and continues to be recognized through awards such as Eric Vivier's Cancer Research Institute Scientific Achievement Award (2026) and Clarivate Highly Cited Researcher distinction (2025).

Name

CIML

Legal name

Centre d'Immunologie de Marseille-Luminy

Website

https://ciml.univ-mrs.fr

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

101–250 employees

Short description

CIML is a French public research institute founded in 1976 in Marseille under joint supervision of Aix-Marseille Université, CNRS, and Inserm. It conducts fundamental immunology research across NK cells, innate lymphoid cells, mucosal immunity, and advanced biophotonic imaging, training doctoral researchers without a commercial revenue model.

Ownership category

akta.pro rank

Headquarters

HQ city

Marseille

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Distribution channels1 record

Marketing channels3 records

Core offering

CIML is a public immunology research institute that conducts fundamental research on the immune system through 27 specialized teams and shared technology platforms. Its activities span innate lymphoid cell and NK cell biology, mucosal immunity, dendritic cells, B cell immunity, and membrane dynamics/lymphocyte signaling, complemented by an educational Master of Immunology program and access to advanced biophotonic and microscopy technologies.

Product overview

CIML (Centre d'Immunologie de Marseille-Luminy) is a renowned immunology research institute founded in 1976, operating under the joint supervision of Aix-Marseille Université, CNRS, and Inserm. The institute conducts fundamental research on the immune system and provides access to technology platforms for the scientific community. CIML also offers an Immunology Master program (labeled amideX PLUS under the TIGER–France 2030 initiative) and publishes scientific publications. It does not offer commercial products or services.

Differentiator

Problem solved

Functional benefit

Products and services

• Immunology Research Programs (27 teams and platforms)
• Master of Immunology Program (amideX PLUS)
• Single-molecule localization microscopy (SMLM) and Quality Control Maps (QCM) technology platform

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• Innate PharmaflagshipStrategic or Co-development Partner · 1 January 1999Biotech company founded in 1999 by Alessandro Moretta (University of Genoa) and Eric Vivier (CIML) based on their NK cell research. Developing NK cell-based immunotherapies and antibody therapeutics targeting NK cell receptors for cancer treatment.
• Aix-Marseille UniversitécoreStrategic or Co-development PartnerOne of the three supervisory institutions of CIML, providing academic oversight and institutional support for the research center
• CNRS (Centre National de la Recherche Scientifique)coreStrategic or Co-development PartnerOne of the three supervisory institutions of CIML, providing national research framework and funding support
• Inserm (Institut National de la Santé et de la Recherche Médicale)coreStrategic or Co-development PartnerOne of the three supervisory institutions of CIML, providing biomedical research oversight and health research framework

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• CNRS: France's largest public research organization and another of CIML's three supervisory bodies. Comparable as the broad national research framework under which CIML operates its immunology programs.
• INSERM: French national institute for health and medical research and one of CIML's three supervisory tutelles. Comparable as a much larger umbrella biomedical research organization, of which CIML is a constituent immunology-focused unit.

Direct peers

• La Jolla Institute for Immunology: Non-profit research institute focused exclusively on immunology, including NK cell and mucosal immunity research that overlaps CIML's Innate Lymphoid Cells team. Direct peer in scale, mission, and scientific scope.
• Max Planck Institute of Immunobiology and Epigenetics: German Max Planck Institute dedicated to immunology and epigenetics research. Direct peer to CIML in size, scope, and fundamental-research positioning, with a similar focus on innate and adaptive immunity.
• Babraham Institute: UK research institute focused on signalling, immunology, and epigenetics. Direct peer to CIML in scale, public funding model, and emphasis on lymphocyte signalling and mucosal biology.
• Institut Curie: French public research center combining basic immunology, cancer biology, and translational research. Highly comparable to CIML in that it conducts fundamental immunology research adjacent to oncology with overlapping PI profiles and joint supervisory structures.
• Francis Crick Institute: Large UK biomedical research institute covering immunology alongside cancer and infectious disease. Peer to CIML in operating model (publicly funded multi-team research center) and in the breadth of fundamental immunology programs.
• Walter and Eliza Hall Institute of Medical Research (WEHI): Australian medical research institute with deep immunology programs, including innate immunity and cell signaling. Comparable to CIML in mission, research breadth, and training-of-researchers mandate.
• Institut Pasteur: Paris-based public research institute with a similarly broad immunology and infectious disease mandate. It is the most structurally comparable French public research center to CIML, operating under mixed public supervision with a major focus on fundamental immunology.
• Broad Institute of MIT and Harvard: Large US biomedical and genomic research institute with significant immunology and cell biology programs. Peer to CIML in conducting fundamental immunology at scale with joint academic governance.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ciml

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CIML